Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Trial · NCT03583086
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Escalation Level 1 (Vorolanib 200 mg +Nivolumab 240mg) | 3 | |
| Overall Study | STARTED | Escalation Level 2 (Vorolanib 300mg + Nivolumab 240mg) | 7 | |
| Overall Study | STARTED | Dose Expansion - Non Small-Cell-Lung Cancer Acquired Resistance | 19 | |
| Overall Study | STARTED | Dose Expansion - Non Small-Cell-Lung Cancer Naive | 15 | |
| Overall Study | STARTED | Dose Expansion - Non Small-Cell-Lung Cancer Primary Refractory | 17 | |
| Overall Study | STARTED | Dose Expansion - Small Cell Lung Cancer - Progressed on Platinum-based Chemotherapy | 18 | |
| Overall Study | STARTED | Dose Expansion - Thymic Carcinoma | 9 | |
| Overall Study | COMPLETED | Escalation Level 1 (Vorolanib 200 mg +Nivolumab 240mg) | 1 | |
| Overall Study | COMPLETED | Escalation Level 2 (Vorolanib 300mg + Nivolumab 240mg) | 1 | |
| Overall Study | COMPLETED | Dose Expansion - Non Small-Cell-Lung Cancer Acquired Resistance | 4 | |
| Overall Study | COMPLETED | Dose Expansion - Non Small-Cell-Lung Cancer Naive | 4 | |
| Overall Study | COMPLETED | Dose Expansion - Non Small-Cell-Lung Cancer Primary Refractory | 2 | |
| Overall Study | COMPLETED | Dose Expansion - Small Cell Lung Cancer - Progressed on Platinum-based Chemotherapy | 2 | |
| Overall Study | COMPLETED | Dose Expansion - Thymic Carcinoma | 1 | |
| Overall Study | NOT COMPLETED | Escalation Level 1 (Vorolanib 200 mg +Nivolumab 240mg) | 2 | |
| Overall Study | NOT COMPLETED | Escalation Level 2 (Vorolanib 300mg + Nivolumab 240mg) | 6 | |
| Overall Study | NOT COMPLETED | Dose Expansion - Non Small-Cell-Lung Cancer Acquired Resistance | 15 | |
| Overall Study | NOT COMPLETED | Dose Expansion - Non Small-Cell-Lung Cancer Naive | 11 | |
| Overall Study | NOT COMPLETED | Dose Expansion - Non Small-Cell-Lung Cancer Primary Refractory | 15 | |
| Overall Study | NOT COMPLETED | Dose Expansion - Small Cell Lung Cancer - Progressed on Platinum-based Chemotherapy | 16 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03583086/flow